Current Appointments & Affiliations
Assistant Professor of Dermatology
·
2021 - Present
Dermatology,
Clinical Science Departments
Recent Publications
Supplemental Patch Testing Identifies Allergens Missed by Standard Screening Series.
Journal Article Dermatitis · 2024 Background: Supplemental patch testing is an adjunct to standard patch test screening series. Objective: To determine the demographics, characteristics, frequency, relevance, and interpretation of patch test reactions for supplemental patch testing. Method ... Full text Link to item CiteDiagnosis and Treatment of Rosacea Fulminans: A Comprehensive Review.
Journal Article Am J Clin Dermatol · February 2018 Rosacea fulminans is a rare inflammatory condition of the central face marked by the abrupt onset of erythematous coalescing papules, pustules, nodules, and draining sinuses. Due to infrequent reporting in the literature, the pathophysiology, classificatio ... Full text Link to item CiteMidline anterior neck inclusion cyst: A novel superficial congenital developmental anomaly of the neck.
Journal Article Pediatr Dermatol · January 2018 BACKGROUND/OBJECTIVES: A variety of congenital developmental anomalies arise on the neck because of the many fusion planes and complex embryologic structures in this region. We describe a series of seven patients with a novel type of superficial midline co ... Full text Link to item CiteRecent Grants
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)(ROCKET-ASCEND)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2028A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)-ROCKET-ASTRO
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2026A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2024View All Grants
Education, Training & Certifications
Case Western Reserve University, Cleveland Clinic Lerner College of Medicine ·
2012
M.D.
Ohio State University ·
2007
B.S.